Form 8-K IMMUNOGEN INC For: Jan 22

Form 8-K IMMUNOGEN INC For: Jan 22

On January 22, 2016, Bayer notified ImmunoGen, Inc. (also referred to as “we,” “our” or “us”) that they had initiated a global Phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343), an anticancer agent utilizing

(Visited 1 times, 1 visits today)
9
Like
Save

Comments

Comments are disabled for this post.